期刊文献+

神经外科患者并发急性肺栓塞的诊治分析 被引量:1

Analysis on diagnosis and treatment of neurosurgical patients with pulmonary embolism
下载PDF
导出
摘要 目的探讨神经外科患者发生肺栓塞(PE)的高危因素及诊治方案。方法回顾性分析2019年5月—2020年4月南京医科大学附属苏州科技城医院神经外科收治的4例合并PE患者的临床资料,占同期重危患者的2.12%(4/189),并结合相关文献进行复习。结果4例中,三叉神经痛、脑膜瘤和脑出血手术后各1例,非手术重型颅脑损伤1例。首发PE距术后或伤后时间平均9.75 d,4例患者均采用国际通用预测肺栓塞风险量表评估,应用抗凝药物后均治愈。结论基于简洁、高效评分的分层管理模式,能够提升肺栓塞患者的早期识别,提高抢救成功率并改善预后。 Objective To discuss the high risk factors and diagnosis and treatment of neurosurgical patients with pulmonary embolism(PE).Methods The clinical data of 4 patients with PE admitted by the Department of Neurosurgery,the Affiliated Suzhou Science&Technology Town Hospital of Nanjing Medical University from May 2019 to April 2020 were analyzed retrospectively,accounting for 2.12%(4/189)of the critically ill patients in the same period,and the related literature were reviewed.Results Among the 4 cases,1 was trigeminal neuralgia,1 was meningioma and 1 was cerebral hemorrhage after operation,and 1 was non operative severe brain injury.The average time from the first PE to the operation or injury was 9.75 days.All 4 patients were evaluated with the international general predictive PE risk scale.All patients were cured after the use of anticoagulants.Conclusion Hierarchical management based on concise and efficient prediction scores will promote early recognition ability,enhance rate of success of treatment and improve prognosis.
作者 李功波 王羽 尹湘怡 邓岩军 王苏纯 朱建兵 朱文昱 黄强 LI Gong-bo;WANG Yu;YIN Xiang-yi(Department of Neurosurgery and Trauma,the Affiliated Suzhou Science&Technology Town Hospital of Nanjing Medical University,Suzhou 215153,China)
出处 《临床神经外科杂志》 2022年第6期707-710,共4页 Journal of Clinical Neurosurgery
基金 苏州市科技计划项目(SYS2020078)。
关键词 肺栓塞 神经外科手术 颅脑重症 高危因素 量表 pulmonary embolism neurosurgery severe craniocerebral disease high risk factor scale
  • 相关文献

参考文献4

二级参考文献68

  • 1Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosisJ J]. Lancet,2012,379(9828) :1835-1846.
  • 2Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest,2008,133(6 SupplJ . 454S-545S.
  • 3Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism[J]. N EnglJ Med, 2013,369(9) : 799-808.
  • 4Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism[J]. N EnglJ Med, 2013 , 368 (8) :699-708.
  • 5Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos,2009,37(l) :74-8l.
  • 6GraffJ, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment[J]. Clin Pharmacokinet,2013,52(4) :243-254.
  • 7Keating GM. Apixaban , a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation[J]. Drugs,2013, 73 (8) :825-843.
  • 8Wang L, He K, Maxwell B, et al. Tissue distribution and elimination of[14CJ apixaban in rats[J]. Drug Metab Dispos, 2011, 39( 2) :256-264.
  • 9Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice[J]. Pharmacotherapy, 2011,31 ( 12) : 1175- 1191.
  • 10Nutescu E, Chuatrisom I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update[J].J Thromb Thrombolysis,2011 ,31 (3) :326-343.

共引文献34

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部